Suchergebnisse - "Lan, Xiaojing"

PubPharm (14)

1

Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer

enthalten in: Cancer research | 2024

von Gai, X. | Liu, Y. | Lan, X. | +16

2

Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis

enthalten in: Pharmacological research | 2023

von Tang, S. | Duan, Y. | Yuan, T. | +14

3

Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy

enthalten in: Journal of medicinal chemistry | 2023

von Gao, D. | Tang, S. | Cen, Y. | +6

4

SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors

enthalten in: Cell research | 2022

von Wang, X. | Chen, Z. | Xu, J. | +33

5

Discovery of PHGDH inhibitors by virtual screening and preliminary structure-activity relationship study

enthalten in: Bioorganic chemistry | 2022

von Zhang, F. | Yuan, L. | Shi, X. | +8

6

Derivados de ((4-(2-oxoimidazolidin-1-il)pirimidin-2-il)amina como inhibidores de IDH mutante para tratar el cáncer

enthalten in: Europäisches Patentamt | 2021

von JIANG LEI | GENG MEIYU | ZHENG QIANGANG | +8

7

PYRIMIDIN-4-YL IMIDAZOLIDINE-2-ONE DERIVATIVES AND COMPOSITIONS HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF

enthalten in: Europäisches Patentamt | 2021

von JIANG LEI | GENG MEIYU | ZHENG QIANGANG | +8

8

((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER

enthalten in: Europäisches Patentamt | 2021

von JIANG LEI | GENG MEIYU | ZHENG QIANGANG | +8

9

Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer

enthalten in: Nature communications | 2019

von Jin, N. | Bi, A. | Lan, X. | +20

10

Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy

enthalten in: European journal of medicinal chemistry | 2018

von Zha, C. | Deng, W. | Fu, Y. | +11